CareDx, Inc. is a commercial stage company. It develops, markets, and delivers a diagnostic surveillance solution for heart transplant recipients. The Company provides AlloMap, a noninvasive blood test used to aid in the identification of heart transplant recipients. It is also pursuing other areas of transplant surveillance, such as the use of cell-free DNA (cfDNA) as a biomarker for rejection. CareDx, Inc. is based in Brisbane, California.
| Revenue (Most Recent Fiscal Year) | $333.79M |
| Net Income (Most Recent Fiscal Year) | $52.55M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | 16.17 |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 2.99 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 2.73 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | 13.67 |
| Pre-Tax Margin (Trailing 12 Months) | 18.05% |
| Net Margin (Trailing 12 Months) | 19.79% |
| Return on Equity (Trailing 12 Months) | 21.16% |
| Return on Assets (Trailing 12 Months) | 14.25% |
| Current Ratio (Most Recent Fiscal Quarter) | 4.11 |
| Quick Ratio (Most Recent Fiscal Quarter) | 3.84 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | 5.54 |
| Book Value per Share (Most Recent Fiscal Quarter) | $7.06 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.19 |
| Earnings per Share (Most Recent Fiscal Year) | $0.93 |
| Diluted Earnings per Share (Trailing 12 Months) | $1.15 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Common Shares Outstanding | 55.68M |
| Free Float | 53.23M |
| Market Capitalization | $1.04B |
| Average Volume (Last 20 Days) | 1.02M |
| Beta (Past 60 Months) | 2.18 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 4.40% |
| Percentage Held By Institutions (Latest 13F Reports) | -- |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |